The Libre 3 CGM is Abbott’s third-generation continuous glucose monitor, a coin-sized sensor worn on the upper arm that streams a new glucose reading to a smartphone every minute for up to 14 days. Users typically compare the Libre 3 CGM against Dexcom G7 and earlier Libre models when choosing a continuous monitor.
What Libre 3 Is and What Changed From Libre 2
Libre 3 reached the US market in 2022 after FDA clearance in May of that year. Compared with Libre 2, the key upgrades are real-time streaming to a smartphone every minute instead of on-demand scanning, a smaller sensor roughly 70% smaller than Libre 2, and a fully integrated transmitter with no separate component to manage.
The sensor is about the size of two stacked US pennies. A thin filament about 5 millimeters long rests in the interstitial fluid just under the skin. The attached electronics sample glucose every minute, and the LibreLink app on your phone receives and displays the data.
How Libre 3 Measures Glucose
Libre 3 uses wired enzyme technology. Glucose in the interstitial fluid reacts with glucose oxidase on the sensor filament, producing a small current that the sensor converts into a glucose estimate. A factory calibration algorithm translates that signal into milligrams per deciliter without requiring fingerstick calibration during wear.
Because interstitial fluid glucose lags capillary blood glucose by 5 to 15 minutes during rapid changes, CGM values can briefly differ from fingerstick readings. The lag shrinks during stable periods and grows after large carbohydrate meals or intense exercise.
Accuracy Performance
The pivotal accuracy study for Libre 3 enrolled 253 adults who wore sensors for up to 14 days while reference venous glucose was measured at 18 controlled laboratory sessions. The overall mean absolute relative difference was 7.9%, with 93% of paired points within 20% of reference. Pediatric MARD in a separate study was 8.7%.
| Metric | Libre 3 | Libre 2 | Dexcom G7 | Guardian 4 |
|---|---|---|---|---|
| Overall adult MARD | 7.9% | 9.2% | 8.2% | 10.6% |
| Sensor wear | 14 days | 14 days | 10 days plus grace | 7 days |
| Warm-up | 60 minutes | 60 minutes | 30 minutes | 2 hours |
| Reading interval | 1 minute | 1 minute scan or alert | 5 minutes | 5 minutes |
| Calibration required | No | No | No | Optional |
Alarm Features
Libre 3 supports urgent low at 55 mg per dL, customizable low between 60 and 100 mg per dL, and customizable high between 120 and 400 mg per dL. Alarms can be silenced for specific time windows, such as meetings or overnight. A signal loss alarm notifies you if the phone loses Bluetooth contact for more than 20 minutes, helpful for caregivers of children or older adults with hypoglycemia risk.
Who Benefits Most From Libre 3
CGMs are most useful for people on multiple daily insulin injections or pumps, those with a history of severe hypoglycemia, and pregnant people with diabetes. ADA Standards of Care recommend CGM for these groups. For adults with type 2 diabetes on basal insulin, CGM use has also shown A1C benefits, and coverage is expanding.
Libre 3 is also used intermittently by people with prediabetes or metabolic syndrome seeking behavioral insights about meals, exercise, and sleep. When used this way, two weeks of data reviewed with a clinician often identifies actionable patterns without long-term CGM commitment. Understanding A1C levels helps contextualize what CGM data means over time.
Application Technique
Apply Libre 3 to the back of the upper arm on clean, dry skin. Avoid insertion over scars, moles, or recent injection sites. The applicator is a single-use device that inserts the filament and secures the sensor adhesive in one motion. Most users report a brief pinprick sensation.
Allow the sensor to bond with skin for 30 seconds before moving. The 60-minute warm-up begins after pairing with the LibreLink app. During warm-up, no glucose data appears, so plan timing around meals and exercise. Overpatches from third-party brands can extend adhesive life through swimming, showering, and vigorous exercise.
Real-World Considerations
Pressure-induced signal loss, sometimes called compression lows, can occur when you sleep on the sensor-bearing arm. Values may drop briefly before returning to normal once pressure releases. Acetaminophen in high doses can interfere with some CGM chemistries, though Libre 3 is less affected than older Dexcom sensors. High-dose vitamin C supplementation has caused falsely low readings in case reports.
Sensor failure rates in postmarket surveillance are approximately 5 to 8%. Abbott typically replaces failed sensors if reported through the LibreLink app within specified windows. Keep one backup sensor on hand to avoid data gaps.
Libre 3 Versus Stelo and Lingo
Abbott also sells Lingo, an over-the-counter CGM aimed at consumers without diabetes, and Libre Rio is planned as an OTC Libre variant. Lingo and Stelo are positioned for general wellness and do not include alarms below 70 mg per dL. Libre 3 remains the prescription, diabetes-focused product with full alarm functionality. If your goal is diabetes management, Libre 3 is the appropriate product; for short-term behavioral insight without diabetes, an OTC CGM may suffice.
Data Sharing With Caregivers and Clinicians
The LibreLinkUp app allows up to 20 caregivers or family members to view your glucose in near real time. LibreView is the cloud platform where clinicians can review ambulatory glucose profile reports during appointments. Data can also be shared with compatible insulin pumps and decision-support software.
The Bottom Line
Libre 3 CGM offers near-best-in-class accuracy, 14-day wear, and real-time alarms in Abbott’s smallest sensor form factor. It is prescription only and remains best suited for people with diabetes on insulin or with hypoglycemia risk, though short-term wear can also inform lifestyle decisions in prediabetes. The American Diabetes Association guide to CGM summarizes current evidence. Discuss with your clinician whether Libre 3 fits your treatment plan and insurance coverage.
This article is for educational purposes only and does not constitute medical advice. Always consult your healthcare provider for diagnosis and treatment decisions.
